Stable lung allograft outcome correlates with the presence of intragraft donor-derived leukocytes

Transplantation

Volumn 66, Issue 9, 1998, Pages 1167-1174

  O'Connell, Peta J ^a,b   Mba Jonas, Adamma ^a   Leverson, Glen E ^a   Heisey, Dennis M ^a   Meyer, Keith C ^a   Love, Robert B ^a   Burlingham, William J ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; AZATHIOPRINE; CYCLOSPORIN; GANCICLOVIR; HLA ANTIBODY; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; TACROLIMUS;

ADULT; AGED; ALLOGRAFT; ARTICLE; BRONCHIOLITIS; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT REJECTION; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE; LUNG LAVAGE; LUNG TRANSPLANTATION; MALE; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0032533781     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199811150-00010     Document Type: Article

References (47)

1. Snell GD. The homograft rejection. Annu Rev Microbiol 1957; 11: 439.
2. Steinmuller D. Immunization with skin isografts taken from tolerant mice. Science 1967; 158: 127.
3. Batchelor JR, Welsh KI, Maynard A, Burgos H. Failure of long surviving, passively enhanced kidney allografts to provoke T-dependent alloimmunity. I. Retransplantation of (AS x AUG)F1 kidneys into secondary AS recipients. J Exp Med 1979; 150: 455.
4. Lafferty KJ, Prowse SJ, Simeonovic CJ, Warren HS. Immunobiology of tissue transplantation: a return to the passenger leukocyte concept. Annu Rev Immunol 1983; 1: 143.
5. Lechler RI, Batchelor JR. Restoration of immunogenicity to passenger cell-depleted kidney allografts by the addition of donor strain dendritic cells. J Exp Med 1982; 155: 31.
6. Lechler RI, Batchelor JR. Immunogenicity of retransplanted rat kidney allografts: effect of inducing chimerism in the first recipient and quantitative studies on immunosuppression of the second recipient. J Exp Med 1982; 156: 1835.
7. Coulombe M, Gill RG. Tolerance induction to cultured islet allografts. I. Characterization of the tolerant state. Transplantation 1994; 57: 1195.
8. Larsen CP, Morris PJ, Austyn JM. Migration of dendritic leukocytes from cardiac allografts into host spleens: a novel pathway for initiation of rejection. J Exp Med 1990; 171: 307.
9. Larsen CP, Steinman RM, Witmer-Pack M, Hankins DF, Morris PJ, Austyn JM. Migration and maturation of Langerhans cells in skin transplants and explants. J Exp Med 1990; 172: 1483.
10. Peugh WN, Austyn JM, Carter NP, Wood KJ, Morris PJ. Inability of dendritic cells to prevent the blood transfusion effect in a mouse cardiac allograft model. Transplantation 1987; 44: 706.
11. Thomson AW, Lu L, Murase N, Demetris AJ, Rao AS, Starzl TE. Microchimerism, dendritic cell progenitors and transplantation tolerance. Stem Cells 1995; 13: 622.
12. Starzl TE, Demetris AJ, Trucco M, et al. Systemic chimerism in human female recipients of male livers. Lancet 1992; 340: 876.
13. Bishop GA, Sun J, Sheil AG, McCaughan GW. High-dose/activation-associated tolerance: a mechanism for allograft tolerance. Transplantation 1997; 64: 1377.
14. Burlingham WJ, Grailer AP, Fechner JH Jr, et al. Microchimerism linked to cytotoxic T lymphocyte functional unresponsiveness (clonal anergy) in a tolerant renal transplant recipient. Transplantation 1995; 59: 1147.
15. Shoskes DA, Wood KJ. Indirect presentation of MHC antigens in transplantation. Immunol Today 1994; 15: 32.
16. Meyer KC, Zimmerman J. Neutrophil mediators, Pseudomonas, and pulmonary dysfunction in cystic fibrosis. J Lab Clin Med 1993; 121: 654.
17. Yousem SA, Berry GJ, Brunt EM, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Lung Rejection Study Group. J Heart Lung Transplant 1990; 9: 593.
18. Yousem SA, Berry GJ, Cagle PT, et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group. J Heart Lung Transplant 1996; 15: 1.
19. Cooper JD, Billingham M, Egan T, et al. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts: International Society for Heart and Lung Transplantation. J Heart Lung Transplant 1993; 12: 713.
20. Ishida H, Kawai T, Tanabe K, et al. Status of microchimerism in recipients 15 years after living related kidney transplantation. Transplantation 1996; 62: 126.
21. Caillat-Zucman S, Legendre C, Suberbielle C, et al. Microchimerism frequency two to thirty years after cadaveric kidney transplantation. Hum Immunol 1994; 41: 91.
22. Schlitt HJ, Hundrieser J, Hisanaga M, et al. Patterns of donor-type microchimerism after heart transplantation. Lancet 1994; 343: 1469.
23. Suberbielle C, Caillat-Zucman S, Legendre C, et al. Peripheral microchimerism in long-term cadaveric-kidney allograft recipients. Lancet 1994; 343: 1468.
24. Starzl TE, Demetris AJ, Trucco M, et al. Chimerism and donor-specific nonreactivity 27 to 29 years after kidney allotransplantation. Transplantation 1993; 55: 1272.
25. Elwood ET, Larsen CP, Maurer DH, et al. Microchimerism and rejection in clinical transplantation. Lancet 1997; 349: 1358.
26. Sivasai KS, Alevy YG, Duffy BF, et al. Peripheral blood microchimerism in human liver and renal transplant recipients: rejection despite donor-specific chimerism. Transplantation 1997; 64: 427.
27. Knoop C, Andrien M, Defleur V, et al. Lung rejection occurs in lung transplant recipients with blood chimerism. Transplantation 1997; 64: 167.
28. Molleston JP, Alevy YG, SivaSai KS, Mohanakumar T, Howard TK. Evidence that pediatric liver transplant recipients may undergo late rejection episodes in spite of donor-specific microchimerism. Transplantation 1996; 61: 656.
29. Schlitt HJ, Hundrieser J, Ringe B, Pichlmayr R. Donor-type microchimerism associated with graft rejection eight years after liver transplantation. N Engl J Med 1994; 330: 646.
30. Fung JJ, Zeevi A, Kaufman C, et al. Interactions between bronchoalveolar lymphocytes and macrophages in heart-lung transplant recipients. Hum Immunol 1985; 14: 287.
31. Sekine Y, Bowen LK, Heidler KM, et al. Role of passenger leukocytes in allograft rejection: effect of depletion of donor alveolar macrophages on the local production of TNF-alpha, T helper 1/T helper 2 cytokines, IgG subclasses, and pathology in a rat model of lung transplantation. J Immunol 1997; 159: 4084.
32. Westra AL, Zeevi A, Dauber J, et al. Clinical significance of the persistence of donor-specific alveolar macrophages in long-term lung transplant patients [Abstract]. J Heart Lung Transplant 1993; 12; S100.
33. Zeevi A, Dauber JH, Yousem SA, et al. Immunologic alterations in chronic lung rejection. In: Shennib H, ed. Immunology of lung allograft. Austin: RG Landes, 1995: 73.
34. Hamano K, Rawsthorne MA, Bushell AR, Morris PJ, Wood KJ. Evidence that the continued presence of the organ graft and not peripheral donor microchimerism is essential for maintenance of tolerance to alloantigen in vivo in anti-CD4 treated recipients. Transplantation 1996; 62: 856.
35. Starzl TE, Demetris AJ, Murase N, Ildstad S, Ricordi C, Trucco M. Cell migration, chimerism, and graft acceptance. Lancet 1992; 339: 1579.
36. Martin DR, Miller RG. In vivo administration of histoincompatible lymphocytes leads to rapid functional deletion of cytotoxic T lymphocyte precursors. J Exp Med 1989; 170: 679.
37. Thomas JM, Carver FM, Kasten-Jolly J, et al. Further studies of veto activity in rhesus monkey bone marrow in relation to allograft tolerance and chimerism. Transplantation 1994; 57: 101.
38. The BAL Cooperative Steering Committee. Bronchoaveolar lavage constituents in healthy individuals, idiopathic pulmonary fibrosis, and selected comparison groups. Am Rev Respir Dis 1990; 141: s169.
39. Reinsmoen NL, Jackson A, McSherry C, et al. Organ-specific patterns of donor antigen-specific hyporeactivity and peripheral blood allogeneic microchimerism in lung, kidney, and liver transplant recipients. Transplantation 1995; 60: 1546.
40. Scott JP, Higenbottam TW, Sharples L, et al. Risk factors for obliterative bronchiolitis in heart-lung transplant recipients. Transplantation 1991; 51: 813.
41. Paradis I, Yousem S, Griffith B. Airway obstruction and bronchiolitis obliterans after lung transplantation. Chest Med 1993; 14: 751.
42. Sharples LD, Scott JP, Dennis C, et al. Risk factors for survival following combined heart-lung transplantation: the first 100 patients. Transplantation 1994; 57: 218.
43. Clubotariu R, Zhuoru L, Colovai AI, et al. Persistent allopeptide reactivity and epitope spreading in chronic rejection of organ allografts. J Clin Invest 1998; 101: 1.
44. Vella JP, Spadafora-Ferreira M, Murphy B, et al. Indirect allorecognition of major histocompatibility complex allopeptides in human renal transplant recipients with chronic graft dysfunction. Transplantation 1997; 64: 795.
45. DeVito-Haynes LD, Jankowska-Gan E, Heisey D, et al. Donor-derived human leukocyte antigen class I proteins in the serum of heart transplant recipients. J Heart Lung Transplant 1996; 15: 1012.
46. DeVito-Haynes LD, Jankowska-Gan E, Heisey DM, et al. Soluble HLA class I in epithelial lining fluid of lung transplants: associations with graft outcome. Hum Immunol 1997; 52: 95.
47. Sundaresan S, Mohanakumar T, Smith M, et al. HLA locus mismatches and development of antibodies to HLA after lung transplantation correlates with the development of bronchiolitis obliterans syndrome. Transplantation 1998; 65: 648.